New horizons in the research on immunization for the blocking of ocular neovascularization induced by the vascular endothelial growth factor

2016, Number 1

Rev Cub Oftal 2016; 29 (1)

Rodríguez RB, González DR

Language: Spanish
References: 3
Page: 1-2
PDF size: 39.26 Kb.

Text Extraction

No abstract.

REFERENCES

Dakin HA, Wordsworth S, Rogers CA, Abangma G, Raftery J, Harding SP. Costeffectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial BMJ Open. 2014 [citado 5 de enero de 2016];4. Disponible en: http://dx.doi.org/10.1136/bmjopen-2014-005094
Consenso latinoamericano sobre la degeneración macular relacionada con la edad. Sociedad Panamericana de Retina y Vítreo. Reunión de Expertos. Febrero, 2012 [citado 5 de enero de 2016]. Dsponible en: http://www.angio.org/wpcontent/uploads/2013/10/Latin_America_AMD_Expert_Sum mit_White_Paper-Spanish.pdf
Morera Y, González R, Lamdan H. Vaccination with a mutates variant of human Vascular Endotelial Growth Factor (VEGT) blocks VEGF-induced rerinal neovascularization in a rabbit experimental model. Experimental Eyes Research. 2014 [citado 5 de enero de 2016];122:102-9. Disponible en: http://dx.dol.org/10.1016/j.exe.2014.03.006